Cibus Q1 FY26 net loss narrows to $21.22 million; revenue rises 63% to $1.68 million

Cibus, Inc. Class A

Cibus, Inc. Class A

CBUS

0.00
  • Cibus posted a net loss of USD 21.22 million, or USD 0.33 per share, for the quarter ended March 31, 2026, narrowing from a year-earlier loss of USD 49.39 million, or USD 1.34 per share.
  • Revenue rose 63% to USD 1.68 million, while operating loss narrowed to USD 12.12 million from USD 41.57 million a year earlier.
  • Research and development expense fell 26% to USD 8.72 million, while SG&A dropped 48% to USD 5.08 million; no goodwill impairment was recorded versus USD 20.95 million a year earlier.
  • Cash and cash equivalents totaled USD 30.3 million at quarter-end, with net cash used in operating activities of USD 11.49 million.
  • Rice herbicide-tolerance traits remained the near-term priority, with an initial Latin America launch targeted for 2027 and U.S. launch pushed to 2029 due to registration timing for chemistry partner Albaugh’s rice herbicide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cibus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-035159), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.